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TITLE OF CASE 
A very unusual case of a primary sinonasal germ cell tumour  
 
SUMMARY 
Sinonasal malignancies are a very rare diagnosis. We present a unique case of a 32 year old man 
who presented with symptoms of worsening sinusitis and periorbital cellulitis. Investigation found a 
sinonasal malignancy and pathology confirmed this to be a primary germ cell tumour. The patient 
was managed with chemotherapy, surgery and consolidation radiotherapy and has remained well to 
date. This case report outlines an unusual presentation and diagnostic challenge for the primary 
care physician, ENT surgeon, pathologist and oncologist with review of the surrounding literature. 
 
BACKGROUND 
Sinonasal malignancies are a rare tumour group. When they do occur, they tend to present in older 
men and are most likely to be either squamous cell carcinoma or adenocarcinoma. Germ cell 
tumours tend to occur in younger people and are most commonly found in the testicles, ovaries or 
with occasional presentation at extragonadal midline sites, commonest being the retroperitoneum. 
We present a case of a 32 year old man with no significant past medical history who was diagnosed 
with a sinonasal malignancy. Further investigation found this to be a primary germ cell tumour. His 
clinical presentation, histology, tumour site and subsequent treatment establish this as a unique case 
in the literature. 
 
CASE PRESENTATION 
A 32 year old gentleman presented to his GP in July 2018 with problematic nasal congestion and 
pain. These symptoms failed to respond to treatment with antibiotics, antihistamine nasal sprays 
and eye drops. After seven weeks, the patient presented to the emergency department acutely with 
new symptoms of swelling in both eyes, feeling feverish with a headache. He had no significant past 
medical history, was on no regular medications, a non-smoker, drank little alcohol and had no 
significant family history. He was married with one daughter.  
 
On examination he had a temperature of 39.5C, right periorbital swelling with proptosis and was 
having difficulty opening his right eye. Bloods tests were normal except for; WCC 26.3 (4.0-10.0 
x10^9/l), Neutrophils 25.0 (2.0-7.0 x10^9/l), Lymphocyte count 0.4 (1.1-5.0 x10^9/l), CRP 162 (0-
10 mg/L), total bilirubin 33 (<20 umol/L). The patient was treated with intravenous antibiotics and 
a computerised tomography (CT) scan was performed as per local protocol for severe periorbital 
cellulitis. CT results prompted an urgent MRI head. 
 
  
INVESTIGATIONS If relevant 
Scans demonstrated a large (40x43x56mm) heterogeneously enhancing mass centred on the 
ethmoid air cells with intracranial extension and adjacent vasogenic oedema within the frontal lobes 
inferiorly. Additionally, there was extension into both orbits and indentation on the medial recti 
muscles bilaterally. Significant fluid and debris were seen in the paranasal sinuses, secondary to 
obstruction of osteomeatal complexes from the mass lesion. Craniocervical junction and CSF spaces 
were unremarkable (Figure 1a). Appearances radiologically were in keeping with an extensive 
sinonasal tumour.  
 
Bedside biopsy was performed following administration of local anaesthetic and decongestant spray 
using a headlight and rigid nasoendoscope. Microscopy showed fragments of fibrous connective 
tissues extensively infiltrated with poorly differentiated tumour cells. There was heterogeneity 
within the biopsy specimen with some areas showing cells with well spaced, squared off nuclei with 
cytoplasmic clearing and some areas of necrosis, brisk mitotic activity and nuclear crowding 
indicating higher grade disease. Keratinisation, gland formation or any evidence of a sarcomatoid 
element were not identified. Immunohistochemistry staining for OCT3/4, PLAP, CAM 5.2 and AE1/3 
were positive. Staining was negative for CD45, NSE, S-100, Melan-A, AFP, Glycipan-3, CD30, CD34, 
CD117. 
 
OCT3/4 (octamer-binding transcription factor 3/4) is expressed by embryonic stem cells and germ 
cells; PLAP (Placental alkaline phosphatase) is an enzyme which is normally present within the 
placenta in the third trimester of gestation; CAM5.2 is a cytokeratin stain that often shows positivity 
in epithelial tumours and AE1/3 is a pankeratin stain is also positive in epithelial tumours.  
 
The OCT3/4 and PLAP positivity indicated that this was likely to be a germ cell tumour. 
Subclassification into seminoma or non-seminomatous disease was challenging however because 
although some areas within the tumour morphologically resembled seminoma, strong cytokeratin 
positivity and absence of CD117 is unusual in this disease entity. The areas of higher grade 
morphology on microscopy raised the possibility of embryonal carcinoma or yolk sac tumour, but 
the absence of CD30 staining ruled out the former and negativity for AFP/Glypican 3 the latter 
(Figure 2a & Figure 2b). 
 
Slides were sent to Professor Reuter at the Memorial Sloan Kettering Cancer Centre in New York for 
specialist review who agreed this was a complicated case but favoured a poorly differentiated 
neoplasm with epithelial differentiation. No definite diagnosis could be reached. 
 
Further laboratory tests showed a serum beta-human chorionic gonadotropin (B-HCG) of 741(<5 
U/L), lactate dehydrogenase (LDH) of 139 (80-240 U/L) and an alpha-feto protein (AFP) of <3 (<7 
kU/L). Testicular ultrasound showed normal testes and epididymis with a small right sided 
hydrocele and CT scan of the patient’s chest/abdomen/pelvis did not reveal any nodal or metastatic 
disease. 
 
Review of the clinical presentation and demographics of the patient, laboratory results, radiological 
findings and pathological information concluded the most likely diagnosis was a germ cell tumour. 
The differential diagnosis at this point was a rare primary sinonasal presentation of a primary germ 
cell tumour, extension from a primary germ cell tumour originating in the central nervous system, or 
a metastatic deposit from a distant primary site in the midline such as gonadal or extragonadal with 
regression of the primary at diagnosis. 
 
  
PET-scan, sperm storage and baseline audiology tests were organised urgently as the standard work 
up prior to treatment with systemic chemotherapy. Unfortunately, whilst awaiting these 
investigations, the patient suffered a prolonged grand-mal seizure. High dose intravenous steroids 
and leviteracetam were commenced.  He was also started on prophylactic co-amoxiclav given the 
sino-nasal invasion and subsequent risk of anaerobic infection. A repeat CT head scan (6 days after 
the initial scan) showed a marginal increase in the size of the intracranial component although the 
quantity of oedema was similar 
 
 
 
DIFFERENTIAL DIAGNOSIS If relevant 
Initial differential diagnoses included sinusitis, periorbital cellulitis or underlying malignancy. Later on, 
the differentials were a rare primary sinonasal presentation of a primary germ cell tumour, 
extension from a primary germ cell tumour originating in the central nervous system, or a 
metastatic deposit from a distant primary site in the midline such as gonadal or extragonadal with 
regression of the primary at diagnosis. 
 
 
TREATMENT If relevant 
Initial treatment 
The risk of neurological deterioration if treatment was delayed was weighed up against the benefits 
of having the optimal staging/work up investigations and it was felt that delaying chemotherapy 
could lead to significant morbidity. The optimal choice of chemotherapy regime was deliberated: 
BEP (bleomycin, etoposide, cisplatin),C-BOP-BEP (carboplatin, bleomycin, vincristine, cisplatin 
followed by bleomycin, etoposide and cisplatin) and VIP (etoposide, ifosfamide and cisplatin) were 
all considered.[1-3] On balance, given the intra-cerebral disease involvement, VIP was chosen 
because of its superior CNS penetration [etoposide 75mg/m2 days 1-5 (D1-5), ifosfamide 
1200mg/m2 (D1-5) and cisplatin 20mg/m2 (D1-5)].  
 
By day 7 of cycle 1 of VIP chemotherapy treatment, the patient’s visual symptoms had normalised 
and by the end of cycle 1 his nasal passages had cleared. B-HCG levels were normal by the end of 
cycle 2 and there was no further seizure activity (Figure 3).  
 
The patient completed four cycles of VIP chemotherapy and end of treatment CT showed a good 
response to treatment with significant reduction in the size of the prior noted ethmoid air cell 
tumour (Figure 1b). However, some residual inflammatory changes within the ethmoid air cells 
were identified, there was multifocal bony dehiscence with chronic inflammatory change and the 
possibility of residual tumour infiltration remained. These images were reviewed at a 
multidisciplinary meeting to decide ongoing management.  
 
Subsequent treatment 
Three months after initial presentation and 3 weeks after the last cycle of chemotherapy, surgical 
resection of the areas of possible residual tumour was performed to ascertain the exact nature of the 
tissue that did not respond. Focal residual viable germ cell tumour in the right anterior skull base 
tissue was detected in the surgical specimen; there was tumour extending up through the skull base 
which was not resected due to concerns of causing a dura breach, CSF leak or CNS contamination 
which would have delayed ongoing management.  
 
  
After discussion at a national multidisciplinary meeting it was felt that local radiotherapy alone after 
chemotherapy would not be sufficient consolidation treatment, and that radiotherapy to both the 
local site and the craniospinal axis was required. The patient consented to receive craniospinal 
radiotherapy (CSRT) after being informed of the likely acute side effects which included headache, 
nausea, diarrhoea, fatigue, alopecia, bone marrow suppression, a temporary reduction in sperm 
count and decreased hearing. Whilst receiving radiotherapy, the patient had significants issues with 
pancytopenia requiring blood product support. He received a total of five units of packed red cells 
and three units of platelets.  
 
Due to the unusual location of the primary disease, acute side effects also envisaged included those 
more in keeping with radiotherapy delivery to the head and neck region. These include pain and 
crusting of the nasal passages, painful mouth, decreased taste and smell, itchy eyes (due to corneal 
dose), sore throat, hoarse voice, dysphagia and oesophagitis. Potential long-term side effects of CSRT 
were explained to the patient; decline in short term memory, pituitary dysfunction, stroke, chronic 
gastritis and gastric ulcers, development of benign tumours such as meningioma and secondary 
malignancy. Again, due to the location of the primary disease and radiotherapy boost, additional 
long term side effects explained were a loss of smell, a dry nasal passage, dry eyes and cataracts. The 
proximity of the primary disease to the pituitary and optic chiasm means that this patient is at risk 
of pituitary dysfunction and visual loss in the future.  
 
Consolidation cranio-spinal radiotherapy (CSRT) was commenced 11 days after the surgical 
procedure. The risk of long term toxicities led to dose contraints. 35Gy in 20 fractions of photon 
radiotherapy was delivered to the craniospinal axis using a volumetric rapid arc intensity modulated 
technique followed by a boost of 20Gy in 12 fractions to the site of gross sinonasal disease at 
presentation (Figure 4). Using VMAT the dose to the optic chiasm was kept below 54Gy which 
confers a longer term risk of visual loss in the region of 1-2%. 
 
 
 
OUTCOME AND FOLLOW-UP 
This patient is now recovering from intensive treatment with normal tumour markers and will be 
followed up regularly by the medical oncologists, radiation oncologists and ENT team. Five months 
on from completion of treatment an MRI showed no sign of recurrence. 
 
Given his treatment with long term high dose steroids and radiation exposure, a referral to the 
endocrinology team will be required at 6-9 months post-diagnosis to assess pituitary function and 
the need for ongoing hormone supplementation. 
 
 
 
 
DISCUSSION Include a very brief review of similar published cases 
Sinonasal malignancies are incredibly rare; making up 1% of all cancers. Only 400 cases are 
diagnosed in the UK each year with a worldwide annual incidence of 1 in 100,000.[4,5] More than 
seventy benign or malignant tumours and tumour-like conditions have been identified.[6] The 
maxillary sinuses and nasal cavity are the most commonly encountered sites of disease, but tumours 
are also found in the ethmoid, sphenoid and frontal sinuses. Patients with sinonasal tumours 
typically present with nasal obstruction followed by facial swelling and epistaxis.[7] They often have 
  
fairly advanced disease at time of presentation.[8,9]  Risk factors include exposure to tobacco 
smoke, air pollution, hardwood dust, formalin, exposure to nickel toxins and leather/textile 
production.[10] There can be significant overlap between clinical and radiological features of benign 
and malignant disease in the nose, making diagnosis difficult.[11] Sinonasal malignancies are most 
commonly seen in males and peak in incidence at age 50-70.  
 
Pre-treatment biopsy is an essential step in management.[12] The most common histological 
subtypes of sinonasal malignancy are squamous cell carcinoma and adenocarcinoma.[13] Other 
histologies include sarcoma, undifferentiated carcinoma, teratocarcinosarcoma, malignant 
melanoma, adenoid cystic carcinoma, lymphoma, olfactory neuroblastoma, neuroendocrine 
carcinoma and nuclear protein in testis carcinoma.[14-17]  
 
Germ cell tumours are a histologically and biologically diverse group of neoplasms. They primarily 
occur in the gonads but can develop at extragonadal sites in the midline of the body.[18] GCTs are 
usually identified as either seminomatous or non-seminomatous and then classified into three 
prognostic groups (good, intermediate or poor) given their primary site, extent of spread and 
tumour markers (AFP, LDH, B-HCG).[19,20] Despite having relatively low tumour marker levels, our 
patient had a primary sinonasal tumour with intracranial extension and was therefore classified as 
poor prognosis. Even when metastatic, cure rates in GCT are high. Five year survival rates of 
metastatic NSGCTs are 92%, 80% and 48% for good, intermediate and poor prognosis disease 
respectively. Good and intermediate prognosis metastatic seminomas have five year survival rates of 
86% and 72%. 
 
There have been very limited presentations of primary sinonasal germ cell tumours occurring in 
adults in the literature and publications tend to be limited to case studies.[21,22] A retrospective 
review of 123 patients with sinonasal malignancies (not exclusively GCT) found that there was no 
significant different between survival rates in those treated with primary radiotherapy, primary 
chemotherapy or primary chemoradiation.[10] In a study looking at outcomes in 11,160 sinonasal 
tumour patients however, therapy with combination chemotherapy, radiotherapy and surgery 
provided favourable outcomes and improved overall survival.[16,23] A further review of 229 
patients supported multimodality treatment, though acknowledged that prognosis is often poor.[7] 
Factors affecting prognosis are multifactorial and include age, gender and ethnicity as well as 
tumour location, histological type, grade and stage.[17] Should the tumour recur, it is most likely to 
do so locally and at an early stage in follow up.[23,24]  
 
Our case demonstrates a unique presentation of a primary sinonasal GCT. Early and effective 
interaction between specialties was vital in providing best possible care in this very rare cancer 
presentation. Communication with the patient was also key given the unusual diagnosis, urgent need 
for intervention, potency of treatment and risk of significant short and long term side effects. 
Prognosis for this specific case remains guarded but the disease is felt to be potentially curable. Our 
patient will be regularly followed up by the ENT team, medical and clinical oncologists. 
 
 
 
  
 
 
LEARNING POINTS/TAKE HOME MESSAGES 3-5 bullet points 
• If a seemingly common illness is not responding to treatment it is worth considering if there is 
something more significant underlying. 
• Once a rare disease is identified it is essential to involve the appropriate specialists as soon as 
possible in order to ensure timely and correct management. 
• Maintaining a good relationship and regular communication with patients is of utmost 
importance when a diagnosis is uncertain or unusual.  
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FIGURE/VIDEO CAPTIONS 
Figure 1a Coronal MRI image at diagnosis  
Figure 1b Coronal MRI image post-chemotherapy and pre-radiotherapy 
Figure 2a - H&E stained section showing a high grade tumour morphology with necrosis and 
cytoplasmic clearing. 
Figure 2b - strong nuclear immunohistochemical positivity for OCT3/4. 
Figure 3 beta-HCG graph 
Figure 4 Sagittal view of radiotherapy dose distribution at the 90% dose level. 
 
 
 
PATIENT’S PERSPECTIVE 
This individual was obviously very surprised by his presentation, diagnosis and treatment. It all happened 
very quickly and he was unwell for a considerable amount of time. Now that he is recovering, he is 
grateful for all of the care he received and the efforts of medical and nursing staff to ensure he received 
the best possible treatment. 
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EXAMPLE OF A WELL PRESENTED CASE REPORT 
Resection of a large carotid paraganglioma in Carney-Stratakis syndrome: a multidisciplinary feat 
 
